SCHEMBL17878557

SCHEMBL17878557

CCCCC(OC(=O)CCC(C)C)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA1 P00915 3/20 0.36
CTSK P43235 2/20 0.36
PRKCA P17252 1/20 0.35
PRKCE Q02156 1/20 0.35
PRKCQ Q04759 1/20 0.35
PRKCD Q05655 1/20 0.35
CA2 P00918 1/20 0.34
FAAH O00519 3/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17878555 0.89 LMNA (0.40) LMNAMAPTMAPK1ALDH1A1CYP3A4
SCHEMBL17882025 0.89 LMNA (0.48) LMNAMAPTMAPK1ALDH1A1CYP3A4
SCHEMBL29131231 0.86 LMNA (0.65) LMNAMAPTMAPK1ALDH1A1CYP3A4
SCHEMBL17860699 0.84 LMNA (0.44) LMNAMAPTMAPK1ALDH1A1CYP3A4
SCHEMBL5962581 0.84 LMNA (0.56) LMNAMAPTMAPK1ALDH1A1PRKCA
SCHEMBL5962564 0.84 LMNA (0.56) LMNAMAPTMAPK1ALDH1A1PRKCA
SCHEMBL2269863 0.83 GPR84 (0.49) LMNAMAPTMAPK1CA1FAAH
SCHEMBL17878556 0.83 CA1 (0.40) LMNAMAPTMAPK1ALDH1A1CYP3A4
SCHEMBL28676563 0.82 LMNA (0.65) LMNAMAPTMAPK1ALDH1A1TSHR
SCHEMBL29577585 0.82 LMNA (0.65) LMNAMAPTMAPK1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS VIP, AQP1, PEF1 LMNA 660/4885MAPT 4274/4885MAPK1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.